Back to top

messenger-rna: Archive

Zacks Equity Research

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

BSXPositive Net Change ECLPositive Net Change ALGNNegative Net Change GEHCPositive Net Change

Zacks Equity Research

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNPositive Net Change PFENegative Net Change NVONegative Net Change AMGNNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

MRKPositive Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change

Zacks Equity Research

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

MRKPositive Net Change MRNAPositive Net Change ANIPNegative Net Change ADMAPositive Net Change

Zacks Equity Research

Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development

Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.

VRTXPositive Net Change ANIPNegative Net Change ADMAPositive Net Change CRSPPositive Net Change